Successful control of Serratia marcescens outbreak in a neonatal unit of a tertiary-care hospital in Spain.


Journal

Enfermedades infecciosas y microbiologia clinica (English ed.)
ISSN: 2529-993X
Titre abrégé: Enferm Infecc Microbiol Clin (Engl Ed)
Pays: Spain
ID NLM: 101777541

Informations de publication

Date de publication:
05 2022
Historique:
received: 06 02 2021
accepted: 06 05 2021
entrez: 16 5 2022
pubmed: 17 5 2022
medline: 20 5 2022
Statut: ppublish

Résumé

Serratia marcescens is a Gram-negative bacterium that is found in hospital environments and commonly associated with outbreaks in neonatal units. One S. marcescens isolate was detected from a bloodstream culture from a neonate in our hospital that was followed by an outbreak. The aim of this study was to describe the molecular epidemiology of a S. marcescens outbreak in the neonatal unit. In order to investigate the outbreak, weekly surveillance rectal swabs were submitted for culture from all patients admitted in this unit from August to September 2018. Environmental samples were obtained from potential sources in September 2018. Typing of isolates was performed by pulsed field gel electrophoresis (PFGE). In addition, we studied the in vitro activity of chlorhexidine against S. marcescens. During this period, 146 infants were hospitalised in our neonatal unit, of which 16 patients had a S. marcescens-positive sample. A total of 36 environmental surveillance samples were collected, and one sample from a stethoscope from an incubator of a colonized baby was positive for S. marcescens. All the 18 isolates, including the isolate from the stethoscope, belonged to a single PFGE cluster. We found that very low concentrations of chlorhexidine, even with application times close to 0 achieved significant reductions in the amount of S. marcescens. A unique clone of S. marcescens caused this outbreak, including isolates from patients and from one stethoscope. The outbreak was controlled with the early implementation of specific control measures.

Identifiants

pubmed: 35577443
pii: S2529-993X(22)00085-5
doi: 10.1016/j.eimce.2021.05.014
pii:
doi:

Substances chimiques

Chlorhexidine R4KO0DY52L

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

248-254

Informations de copyright

Copyright © 2021 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved.

Auteurs

María Isabel Millán-Lou (MI)

Servicio de Microbiología, Hospital Universitario Miguel-Servet, Zaragoza, Spain; Instituto de Investigación Sanitaria de Aragón (IIS Aragón), Zaragoza, Spain. Electronic address: isiml68@gmail.com.

Concepción López (C)

Servicio de Microbiología, Hospital Universitario Miguel-Servet, Zaragoza, Spain.

Jessica Bueno (J)

Servicio de Microbiología, Hospital Universitario Miguel-Servet, Zaragoza, Spain; Instituto de Investigación Sanitaria de Aragón (IIS Aragón), Zaragoza, Spain.

Vanesa Pérez-Laguna (V)

Instituto de Investigación Sanitaria de Aragón (IIS Aragón), Zaragoza, Spain. Electronic address: perezlaguna@evolbio.mpg.de.

Carlos Lapresta (C)

Servicio de Medicina Preventiva, Hospital Universitario Miguel-Servet, Zaragoza, Spain.

María Elena Fuertes (ME)

Unidad de neonatología, Hospital Universitario Miguel-Servet, Zaragoza, Spain.

Segundo Rite (S)

Unidad de neonatología, Hospital Universitario Miguel-Servet, Zaragoza, Spain.

Mónica Santiago (M)

Servicio de Microbiología, Hospital Universitario Miguel-Servet, Zaragoza, Spain.

María Romo (M)

Servicio de Microbiología, Hospital Universitario Miguel-Servet, Zaragoza, Spain.

Sofia Samper (S)

Instituto de Investigación Sanitaria de Aragón (IIS Aragón), Zaragoza, Spain.

Alberto Cebollada (A)

CIBERES, ISCIII, Madrid, Spain; Departamento de Microbiología, Medicina Preventiva y Salud Pública, Universidad de Zaragoza, Zaragoza, Spain; Unidad de Biocomputación, Instituto Aragonés de Ciencias de la Salud (IACS/IIS Aragón), Zaragoza, Spain.

Jesús Oteo-Iglesias (J)

Laboratorio de Referencia e Investigación en Resistencia a Antibióticos, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain.

Antonio Rezusta (A)

Servicio de Microbiología, Hospital Universitario Miguel-Servet, Zaragoza, Spain; Instituto de Investigación Sanitaria de Aragón (IIS Aragón), Zaragoza, Spain; Departamento de Microbiología, Medicina Preventiva y Salud Pública, Universidad de Zaragoza, Zaragoza, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH